Advancing Equity, Precision, and Awareness in Dermatology

As February proceeds, we recognize 2 important observances: Black History Month and Rare Disease Day. Black History Month presents an opportunity to reflect on the significant contributions of Black clinicians, scientists, and researchers to dermatology, while also underscoring the ongoing responsibility to enhance care for patients with skin of color. Dermatology clinicians play a critical role in closing persistent gaps in equity and outcomes.

This issue highlights clinical insights relevant to inflammatory conditions in diverse populations, emphasizing practical strategies for everyday practice. We also acknowledge Rare Disease Day as a reminder of the importance of early recognition and multidisciplinary collaboration when caring for patients with uncommon dermatologic conditions. Stay tuned to DermatologyTimes.com for in-depth discussions of rare dermatologic conditions to be aware of.

This month’s cover feature by Aaron Farberg, MD, covers the 487-gene expression profile test for moderate to severe atopic dermatitis (AD). Approximately 40% of patients with AD who start taking a Th2-targeted biologic eventually need to add or switch to another therapy. Using a noninvasive skin scraping, the AdvanceAD-Tx test applies machine-learning algorithms to classify patients into one of 2 profiles: a Janus kinase inhibitor responder profile or a Th2 molecular profile. Continue reading inside to learn how this test could improve therapy selection for patients with AD.

Other important features in this issue include an in-depth look at the UV risks associated with snow sports with US Olympian Travis Ganong and dermatologist Whitney Hovenic, MD. Additionally, data from a recent study linked chemical hair straighteners and relaxers to an increased lifetime cancer risk. Despite these findings, Amy McMichael, MD, expressed concerns with the misclassification of grouping distinct hair products together without specifying the product type or chemical components.

As always, Dermatology Times delivers the most up-to-date clinical content, featuring innovative studies, FDA approvals, exclusive interviews, and expert perspectives. Stay informed with the latest data—subscribe to Dermatology Times’ e-newsletters and follow us on Facebook, LinkedIn, and X.

With the start of the new year, Dermatology Times welcomes clinicians to submit clinical, original manuscripts for publication consideration to DTEditor@mmhgroup.com.